Panbela Therapeutics EBITDA 2020-2024 | PBLA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Panbela Therapeutics ebitda from 2020 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Panbela Therapeutics ebitda from 2020 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$142.2B
Bristol Myers Squibb (BMY)	$117.1B
Gilead Sciences (GILD)	$117.1B
Vertex Pharmaceuticals (VRTX)	$105.1B
CSL (CSLLY)	$85.9B
Regeneron Pharmaceuticals (REGN)	$78.5B
GSK (GSK)	$70.5B
Argenex SE (ARGX)	$38B
Alnylam Pharmaceuticals (ALNY)	$31.4B
BioNTech SE (BNTX)	$27.4B
Biogen (BIIB)	$21.7B
Illumina (ILMN)	$21.4B
BeiGene (BGNE)	$17.7B
Moderna (MRNA)	$15.5B
Genmab (GMAB)	$13.5B
Incyte (INCY)	$13.5B
BioMarin Pharmaceutical (BMRN)	$12.7B
Insmed (INSM)	$12.6B
Sarepta Therapeutics (SRPT)	$11.6B
Bio-Techne Corp (TECH)	$11.6B
Exact Sciences (EXAS)	$10.8B
Vaxcyte (PCVX)	$10.7B
QIAGEN (QGEN)	$10.3B
Swedish Orphan Biovitrum (BIOVF)	$9.8B
Exelixis (EXEL)	$9.7B
Bio-Rad Laboratories (BIO.B)	$9.1B
Intra-Cellular Therapies (ITCI)	$9B
Roivant Sciences (ROIV)	$8.7B
Ascendis Pharma (ASND)	$8.4B
Repligen (RGEN)	$8.2B